PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)

Recruiting in Palo Alto (17 mi)

+68 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Boehringer Ingelheim

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

To demonstrate that Telmisartan combined with Hydrochlorothiazide (MICARDIS® HCT) is superior to Losartan with Hydrochlorothiazide (Hyzaar®) in lowering blood pressure in mild-moderate hypertensives.

Research Team

Boehringer Ingelheim Study Coordinator

Principal Investigator

Boehringer Ingelheim

Eligibility Criteria

Inclusion Criteria

Ability to provide written informed consent in accordance with GCP and local legislation.

Mild-to-moderate hypertension defined as a mean seated DBP of >= 95 mm Hg and <=l to 109 mm Hg, measured by manual cuff sphygmomanometer at Visit 2.

Male or Female >= 18 years.

Treatment Details

Interventions

• Losartan/Hydrochlorothiazide (Hyzaar®) (Angiotensin II Receptor Blocker with Diuretic)
• Telmisartan/Hydrochlorothiazide (MICARDIS® HCT) (Angiotensin II Receptor Blocker with Diuretic)

Who Is Running the Clinical Trial?

Boehringer Ingelheim

Lead Sponsor

Trials

2,566

Recruited

16,150,000+